27 April 2023
If you are covering AstraZeneca’s latest financial results, please find below a comment from Sheena Berry, equity research analyst at Quilter Cheviot:
“AstraZeneca has delivered a good start to 2023 with some of the key growth products delivering solid performance. The company has maintained its full-year guidance and its growth outlook remains attractive given its busy pipeline.
“AstraZeneca has started six new phase three trials this year and remains on track to initiate 30 over the course of 2023. The pipeline underpins the business and makes it look more attractive compared to peers.
“A number of trials will deliver pivotal results over the next year, but the main focus is currently on the upcoming data readout of the Dato-Dxd refractory lung cancer trial, which if successful has blockbuster potential and will help give positive momentum across the business.”
